`
`
`
`
`Not for Publication
`
`
`UNITED STATES DISTRICT COURT
`DISTRICT OF NEW JERSEY
`
`
`
`
`
`
`
`
`:
`
`
`
`
`
`JAZZ PHARMACEUTICALS, INC.,
`:
`et al.,
`
`
`
`
`:
`
`
`
`
`
`
`:
`
`
`
`Plaintiffs,
`
`:
`
`
`
`
`
`
`:
`
`
`
`v.
`
`
`:
`
`
`
`
`
`
`:
`AMNEAL PHARMACEUTICALS,
`:
`LLC, et al.,
`
`
`
`
`:
`
`
`
`Defendants.
`
`:
`
`
`
`
`
`
`:
`
`
`
`
`Civil Action No. 13-391 (ES) (JAD)
`
`
`
`
`
`ORDER
`
`Pending before the Court is Watson Laboratories, Inc.’s (“Watson”) motion to dismiss
`
`several counts of a complaint for patent infringement filed by Jazz Pharmaceuticals, Inc. and
`
`Jazz Pharmaceuticals Ireland Limited (collectively, “Jazz”). (D.E. No. 13, Civil Action No. 14-
`
`7757). In Counts VIII, IX, X, XI, XII, XIII, and XIV of its complaint, Jazz alleges patent
`
`infringement of U.S. Patent Nos.: 7,668,730; 7,765,106; 7,765,107; 7,895,059; 8,457,988;
`
`8,589,182; and 8,731,963 (collectively, the “Risk Mitigation Patents”), respectively. (D.E. No.
`
`1, Civil Action No. 14-7757). Watson moves to dismiss these counts under Federal Rule of Civil
`
`Procedure 12(b)(6) on the grounds that the “Risk Mitigation Patents” claim ineligible subject
`
`matter under 35 U.S.C. § 101.
`
`The Court has been informed, however, that Petitions for Inter Partes Review (“IPR”)
`
`under 35 U.S.C. §§ 311-19 have been filed concerning the Risk Mitigation Patents. These
`
`Petitions ask the U.S. Patent and Trademark Office’s Patent Trials and Appeals Board (“PTAB”)
`
`
`
`- 1 -
`
`
`
`Case 2:13-cv-00391-ES-JAD Document 185 Filed 11/03/15 Page 2 of 2 PageID: 2338
`
`
`to institute IPR review and cancel all claims of the Risk Mitigation Patents under 35 U.S.C. §
`
`103. (See D.E. Nos. 160 & 164, Civil Action No. 13-391).
`
`Pursuant to a status conference with the parties on November 3, 2015, and further in the
`
`Court’s discretion and interest to efficiently manage its docket, it is hereby
`
`ORDERED that Watson’s motion to dismiss is ADMINISTRATIVELY TERMINATED
`
`over Watson’s objection, with leave to re-file at a date to be determined by the Court after the
`
`PTAB resolves the pending IPR petitions.
`
`
`SO ORDERED.
`
`Date: November 3, 2015.
`
`s/Esther Salas
`Esther Salas, U.S.D.J.
`
`
`
`
`
`
`
`- 2 -
`
`